Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02588092 · ClinicalTrials.gov registry record · Phase 1
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02588092 is a Phase 1 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 35 participants.
The verdict
NCT02588092, a Phase 1 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study evaluates ADCT-301 in participants with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). Participants will participate in a dose-escalation phase (Part 1) and receive ADCT-301 either weekly or once every 3 weeks. In Part 2 of the study, participants will receive a recommended dose of ADCT-301 as determined by a Dose Escalation Steering Committee.
Interventions
- DRUG ADCT-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2018-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02588092
The ClinicalTrials.gov registry entry for NCT02588092 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADCT-301 is the first listed.
NCT02588092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02588092 about?
NCT02588092 is a clinical study titled "Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)". This study evaluates ADCT-301 in participants with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). Participants will participate in a dose-escalation phase (Part 1) and receive ADCT-301 either weekly or once every 3 weeks. In Part 2 of the study, participants will receive a reco...
What is the current status of trial NCT02588092?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2016-02-01. Estimated completion is 2018-08-29.
What interventions are being tested in trial NCT02588092?
The interventions under investigation include: ADCT-301 (DRUG).
Who is sponsoring clinical trial NCT02588092?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.